Formestane Lentaron 566-48-3 for Female Estrogen Receptor-Positive Breast Cancer Treatment

Formestane Lentaron 566-48-3 for Female Estrogen Receptor-Positive Breast Cancer Treatment

Quick Detail Product Description Introduction Formantane (trade name Lentaron), also known as 4-hydroxyandrost-4-ene-3,17-dione, is a type I, steroid, selective aromatase inhibitor. It is used for the treatment of postmenopausal women with estrogen receptor-positive breast cancer. The drug is...

Product Details

Quick Detail

Product Name

Formestane

CAS NO

566-48-3

Assay

99% above

Molecular Weight

302.408

Density

1.2±0.1 g/cm3

Boiling Point

475.4±45.0 °C at 760 mmHg

Molecular Formula

C19H26O3

Melting Point

199-202°C

Flash Point

255.4±25.2 °C

Appearance

White Powder

Packaging

1kg foil bag

Price

1588-2382USD/KG

MOQ

1kg

Sample

Availability

Origin China

China

Payment Term

TT/West Union/Money Gram/Bitcoin

Delivery Time

3-5 working days by express normally

Product Description

Introduction

Formantane (trade name Lentaron), also known as 4-hydroxyandrost-4-ene-3,17-dione, is a type I, steroid, selective aromatase inhibitor. It is used for the treatment of postmenopausal women with estrogen receptor-positive breast cancer. The drug is not an oral active substance, but is used only as an intramuscular injection dose. Thus, many oral active aromatase inhibitors have been identified and introduced and are no longer welcome. Methanesulfonic acid is a androstenedione analog.

The use of methanesulfonic acid is usually used to inhibit the production of estrogen in the metabolic steroids or hormones. It also acts as a hormone for 4-hydroxy testosterone (an active steroid), showing weak male androgen activity in addition to being a weak aromatase inhibitor.

Structure

图片31.jpg

Spectrum


图片32.jpg


Applications

Methanesulfonic acid (4-hydroxyandrostenedione) is an aromatase inhibitor, which significantly reduces the plasma levels of estrogen and exhibits antitumor activity in postmenopausal women with breast cancer. Intraperitoneal injection of limestone is 250 or 500 mg during treatment, once every 2 weeks, of which 20% to 30% of patients experience disease stability. Median time is 8 to 14 months. In soft tissue metastases, the highest response rate was observed in patients with estrogen-reactive tumors and in patients who responded to previous endocrine therapy. In addition, there is some evidence that methanesulfonic acid 500 and 250 mg once every 2 weeks to achieve a higher response rate. In a comparative study, the clinical efficacy of intramuscular methanesulfonic acid 250 mg was not significantly different from that of oral methotrexate as a second-line endocrine therapy given to patients with advanced tamoxifen-treated late-stage disease. In addition, the response rate, duration of response, and overall survival rate of methotrexate were not significantly different from oral tamoxifen when treated as first-line endocrine therapy in patients with advanced disease, but in some measures, Fen better. Further investigation of these two drugs, including higher doses of methanesulfonic acid (500 mg), is necessary to determine its relative efficacy. Most patients have well tolerated methanesulfonic acid; adverse events rarely need to stop treatment. The most common adverse event is the local response to the injection site, and systemic events are usually associated with the effects of the drug on the hormonal environment. The systemic tolerance of methanesulfonamate is similar to tamoxifen, but better than megestrolone. Therefore, as a first-line endocrine treatment of advanced disease, methanesulfonamide is effective and well tolerated. However, at present, it is not possible to challenge tamoxifen in this symptom, according to the latest findings of large comparative studies and the fact that methanesulfonic acid requires intramuscular administration. Despite this, it seems to have a better tolerance than other currently available second-line drugs (including medroxyprogesterone and aromatase inhibitor aminosuccinimide) is a second-line treatment for postmenopausal women with advanced breast cancer Valuable drugs.

Our Service

1.Quality Product and Good Price

We offer absolute high quality product in customized or non-customized. If there are any problems in quality, please contact me as soon as possible.

2. Fast &Secure Shipping

Generally, for small quantity product, the product will be shipped by courier.

For bulk goods, usually you will receive the product within 15 working days.

The rate of passing customs is more than 90%.

3. Reshipping Policy

Even for the worst situation when the product is blocked by the customs, we can reship the product without any extra payment for the product.

4. Technical Supports

Our lab can customize the right product and support u with our top specialists. So if u have a recipe and need help just inform us. We can make experiments and get a good result.

FAQ

1 What about the payment?Is it secure?

Payment can be TT, West Union, Money Gram and Bitcoin. As a well-known supplier, thousands of buyers pay as mentioned. It is warmly welcome to visit our company, discuss and deal face to face.

2 How can I ensure I get the right product?

Before placing an order, you first call us getting specific information like purity, quantity, usages, packing terms, stocking conditions etc. The more details you offer the better result you can have. When shipping, our service center will inform you with the tracking number, packing terms and quantity.

3 How to contact us directly?

Please feel free to contact me:
Contact:claire
E-mail:claire@chembj.com
Skype:live:695059711
Whatapp:+8618123714275

Inquiry